ReviewReproductive sciences (Thousand Oaks, Calif.)2025
Preventing Preterm Birth: The Search for Tocolytic Synergism.
Review in Reproductive sciences (Thousand Oaks, Calif.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Liquid Biopsy in Uterine Leiomyosarcoma: Current Biomarkers, Emerging Technologies, and Future Perspectives.Current oncology reports · 2026Review
- Targeted downmodulation of OXTR and Cx43 in the myometrium by SERTIs as a novel tocolytic strategy.Uterine research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preterm birth is a common cause of neonatal mortality and morbidity, which are increasingly prevalent today. Preterm birth affects millions of babies worldwide and is the subject of intense study in its pathophysiology and therapy. Tocolytic agents are drugs used to prevent preterm birth and prolong pregnancy, to allow the fetus to remain in utero for further maturation, permit antenatal corticosteroid treatment to accelerate fetal lung maturity, and allow enough time for in utero-transfer of the baby to a tertiary care facility. However, the application of traditional tocolytic therapy is often limited due to maternal and fetal side effects. As such, there is a pressing need for safer and more effective tocolytic therapy. Combinational tocolysis has the potential to improve tocolytic efficacy and reduce side effects. A limited number of papers have revealed the prospective benefits of combinational tocolysis by drug synergism and reduced drug toxicity. This review summarizes the current landscape of combinational tocolysis directed at achieving tocolytic synergism and examines the quantitative methods utilized for detecting synergistic tocolytic combinations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.